Optiscan Imaging Ltd
Optiscan Imaging Launches First Clinical Device into US Veterinary Market
Optiscan debuts InSpecta as its first US commercial clinical imaging device after FDA CVM submission, unlocking US sales in a $15.9B market.
Optiscan Submits FDA Dossier for Inspecta Imaging Device Targeting Lucrative US Veterinary Market
Optiscan submits FDA dossier for InSpecta veterinary imaging, unlocking US$11.9B market with real-time, non-invasive imaging for pets.
Optiscan Imaging Launches Head and Neck Cancer Study Using Invue and InForm Digital Pathology Tools
Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch the nation’s first-in-human head and neck cancer imaging study utilising the InVue and InForm digital pathology devices.
Optiscan Imaging and Mayo Clinic to collaborate on robotic breast cancer surgery technology
Optiscan Imaging (ASX: OIL) and US medical group Mayo Clinic have joined forces to advance the development of a digital confocal laser endomicroscopic imaging system for use in robot-assisted breast cancer surgery. The two parties are conducting the work as part of the 24-month “know-how” agreement they signed in May 2024, bringing together experts from […]